Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Overview
Liquidia Corporation (LQDA) is a United States-based biopharmaceutical company dedicated to transforming therapy development for pulmonary hypertension and other rare cardiopulmonary diseases. Utilizing its proprietary PRINT® Technology, the company engineers precise, uniform drug particles to optimize drug delivery and improve treatment efficacy. This innovative approach addresses critical gaps in current therapeutic options, ensuring products are manufactured under scalable, cGMP-compliant processes.
Core Technology and Business Model
At its core, Liquidia harnesses the power of PRINT® Technology to overcome common challenges in drug delivery. By producing highly controlled and uniform particles, the company enhances deposition in the lungs, which is vital for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia’s model includes both the advancement of its own pipeline and strategic licensing of its technology to globally recognized pharmaceutical partners.
Product Portfolio and Clinical Focus
Liquidia’s primary product candidate, YUTREPIA™ (treprostinil) inhalation powder, exemplifies its application of precision particle engineering for the treatment of PAH and PH-ILD. The company is also developing additional candidates and formulations, including a sustained-release liposomal version designed for twice-daily administration, further diversifying its clinical offerings. This broad clinical focus reinforces Liquidia’s commitment to addressing unmet patient needs.
Market Position and Competitive Landscape
Positioned in a competitive biopharmaceutical landscape, Liquidia distinguishes itself through its unique technological platform and rigorous adherence to quality standards. Its scalable PRINT® process, combined with robust clinical research and strategic partnerships, offers a scientifically sound alternative in a market with significant unmet needs. Industry-specific terms such as "drug particle engineering", "inhaled therapeutics", and "cGMP compliance" attest to the company’s technical expertise and operational rigor.
Operational Excellence and Regulatory Focus
Liquidia’s operations are streamlined across its specialized subsidiaries, ensuring efficient research, development, and commercialization processes. The company maintains a strict focus on quality by aligning its manufacturing practices with the highest regulatory standards, hence building a foundation of trust and reliability in its product offerings. This diligence in quality control and regulatory adherence solidifies its reputation within the oncology and pulmonary care communities.
Industry Collaboration and Strategic Partnerships
Liquidia actively collaborates with major pharmaceutical entities, both to license its PRINT® platform and to accelerate the commercialization of its products. These partnerships allow for a mutual exchange of expertise and resources, further enhancing its market reach and ensuring that advanced therapies are delivered efficiently. Such strategic alliances are critical for fostering innovation and establishing a competitive advantage in the complex healthcare landscape.
Commitment to Innovation and Quality
With a commitment to continuous innovation, Liquidia leverages extensive clinical studies and state-of-the-art manufacturing processes to bring safer and more effective treatment options to patients. Emphasizing precision in every phase of development, the company sets itself apart by ensuring that its therapies are optimally designed to tackle the challenges of pulmonary hypertension and related ailments.
Liquidia Corporation (NASDAQ: LQDA) will report its second quarter 2021 financial results on August 10, 2021. A conference call and webcast are scheduled for 8:30 a.m. EDT, where the company will discuss financial outcomes and provide a corporate update. Interested parties can access the call via telephone or the webcast available on Liquidia's website. The company focuses on developing treatments for pulmonary hypertension through its PRINT® Technology, with ongoing projects like LIQ861 and Treprostinil Injection.
On June 7, 2021, United Therapeutics Corporation (Nasdaq: UTHR) announced it is pursuing trade secret misappropriation claims against Liquidia Technologies, Inc. (Nasdaq: LQDA) and a former employee. The lawsuit stems from evidence suggesting the employee took confidential documents to Liquidia during the development of LIQ861, a product competing with United Therapeutics' Tyvaso. The FDA's approval of LIQ861 is on hold pending the outcome of the litigation, which is scheduled for trial in March 2022. United Therapeutics seeks monetary and injunctive relief due to these allegations.
Liquidia Corporation (NASDAQ: LQDA) announced on June 2, 2021, that the FDA accepted its New Drug Application (NDA) resubmission for LIQ861, an inhalation powder for treating pulmonary arterial hypertension (PAH). The resubmission is a complete, class 2 response to a prior FDA action letter from November 24, 2020. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 7, 2021, for potential approval. However, final approval may be subject to ongoing legal issues with United Therapeutics and a regulatory stay that ends in October 2022.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, from 2:30 to 2:55 p.m. EDT. The session aims to provide an overview and update on the company's business strategies and developments. Investors and interested parties can access the live webcast through the Liquidia website, and an archived version will be available for 90 days post-event. Liquidia is focused on developing treatments for pulmonary hypertension using its proprietary PRINT® Technology.
Liquidia Corporation announced the availability of Sandoz Treprostinil Injection, a generic version of Remodulin®, for both subcutaneous and intravenous administration to treat pulmonary arterial hypertension (PAH). This is the first fully-substitutable generic option, providing lower-cost treatment alternatives. The RG 3ml Medication Cartridge has been cleared by the FDA, allowing for the SC administration of the medication, previously restricted. Liquidia aims to maintain high support levels while offering competitive pricing for patients.
Liquidia Corporation (NASDAQ: LQDA) announced a significant market expansion for Treprostinil Injection due to the introduction of subcutaneous delivery, nearly doubling its addressable market. The company also resubmitted its NDA for LIQ861 (treprostinil) Inhalation Powder to the FDA, aiming for a six-month review. Financially, they improved their position with a private placement raising $21.7 million and new credit facilities. First-quarter revenue stood at $3.1 million compared to none last year, and a net loss of $9.2 million was reported.
Liquidia Corporation (NASDAQ: LQDA) has resubmitted its New Drug Application (NDA) for LIQ861, targeting pulmonary arterial hypertension (PAH). The FDA issued a Complete Response Letter (CRL) in November 2020, citing incompleteness. Following a Type A meeting in January, the new NDA now includes additional chemistry and manufacturing details, but no new clinical data was required. The FDA plans to classify this resubmission as a Class 2, which entails a six-month review cycle. Liquidia is ready for required on-site inspections delayed by COVID-19.
Liquidia Corporation (NASDAQ: LQDA) will announce its first quarter 2021 financial results on May 13, 2021. The company will conduct a conference call at 8:30 a.m. EDT to discuss these results and provide a corporate update. Interested parties can join the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code: 2007727. The event will also be available via webcast on Liquidia's website, with an archive for later viewing.
Liquidia Corporation (NASDAQ: LQDA) announced a private placement agreement with accredited investors to sell 8,626,037 shares of common stock at $2.52 per share, raising approximately $21.7 million. The closing is set for today, with David Johnson from Caligan Partners LP joining the board. This funding aims to enhance commercial capabilities for LIQ861 and Treprostinil Injection, supporting growth initiatives. The company has agreed to file a registration statement to register the resale of shares within 180 days post-closing.
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, from 1:30 to 2:10 p.m. EST. This event can be accessed via a live webcast on Liquidia's website, with a recorded version available for 90 days post-event. Liquidia focuses on pulmonary hypertension treatments and utilizes its PRINT® Technology for developing innovative products like LIQ861 and LIQ865.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
What is Liquidia Corporation's core business?
How does PRINT® Technology enhance drug delivery?
Which therapeutic areas does Liquidia focus on?
How does Liquidia generate revenue?
What differentiates Liquidia from its competitors?
How does Liquidia ensure the quality and safety of its products?
What role do strategic partnerships play in Liquidia’s business model?
